July 29, 2026
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







